# What a blood test in young athletes can tell us about MOTS-c

- Article ID: research-260
- Product: MOTS-C (mots-c-698)
- Canonical page: https://heritagebiolabs.com/research-library/articles/260-what-a-blood-test-in-young-athletes-can-tell-us-about-mots-c
- Product collection: https://heritagebiolabs.com/research-library/products/mots-c
- Product page: https://heritagebiolabs.com/product/mots-c-698
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2019, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some serve as signals that change as cells respond to their environment. MOTS-c is a 16-amino-acid peptide encoded in a region of mitochondrial DNA. A 2026 study asked whether the amount of MOTS-c measured in blood was associated with exercise capacity in young men. [1, 2]

Researchers studied 30 healthy men aged 18 to 25, with ten elite track and field athletes, ten recreationally active participants, and ten sedentary participants. The athletes had the highest average measured MOTS-c, followed by the recreationally active and sedentary groups. Higher measured MOTS-c was associated with higher maximal oxygen uptake and some other fitness and antioxidant measures. The authors did not find a significant relationship with handgrip strength. [1]

The design was cross-sectional. Investigators grouped participants by their existing activity and compared measurements made during the study. The groups could have differed in training history, diet, body composition or other characteristics that were already present. The study therefore shows that some measures varied together. It does not establish whether exercise changed the amount of peptide, whether the peptide influenced fitness, or whether a third factor contributed to both observations. [1]

There is also a difference between measuring a peptide already present in the body and testing an administered product. In its July 2026 compounding briefing, FDA said it had not identified human exposure data on drug products containing native MOTS-c. A separate clinical registry lists CB4211 as the intervention in an early study. That record describes CB4211 and provides no trial of native MOTS-c. A study of naturally circulating levels cannot fill the same evidentiary role as a controlled administration study. [1, 2, 3]

## Sources

1. Z. Zhang et al. Associations of Serum MOTS-c with Exercise Capacity and Antioxidant Markers in Young Males: A Cross-Sectional Study. Antioxidants (publication 2026-10-01). <https://pubmed.ncbi.nlm.nih.gov/42939841/>
2. U.S. Food and Drug Administration. FDA Evaluation of MOTS-c – Related Bulk Drug Substances (MOTS-c (free base) and MOTS-c acetate). Pharmacy Compounding Advisory Committee briefing (publication 2026-07-23). <https://www.fda.gov/media/193347/download>
3. CohBar, Inc. A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. ClinicalTrials.gov (publication 2019-06-26). <https://clinicaltrials.gov/study/NCT03998514>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 052 - MGF and MOTS-C.docx; article 260; content SHA-256 c94405bbc3b8b1cb08dca05f02202679e06fb2e2ddb1393657d7d3d3d83790e5.
